Innovation & Research

Clinical trials database

The information given herein regards the clinical studies conducted by the Menarini Group and is not intended for promotional or marketing purposes, nor is it meant to replace the advice of the physician, who is ultimately responsible for the choice of the most suitable treatment for the individual patient.

Clinical Trials Results


DATASHARING


LOGIN

Medical Condition
Compound
Phase
Status
Requirements
 
Acute Myeloid Leukemia
SEL24/MEN1703
I/II
Recruiting
≥18 Years
A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia (DIAMOND-01)
Acute Myeloid Leukemia
MEN1112
I
Recruiting
≥18 Years
First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia (ARMY-1)
Breast Cancer
MEN1611
I
Recruiting
≥18 Years
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer (B-PRECISE-01)
Colorectal Cancer
MEN1611
I/II
Recruiting
≥18 Years
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
Solid Tumors/ Non-Hodgkin Lymphoma
MEN1309
I
Terminated
≥18 Years
MEN1309 Intravenous Infusion in Patients With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory Non-Hodgkin Lymphoma Phase I Study (CD205-SHUTTLE)
Ovarian cancer
Abagovomab
II/III
Terminated
≥18 Years
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)

Recruitment status:

NOT YET RECRUTING: The study has not started recruiting participants
RECRUITING: The study is currently recruiting participants.
ACTIVE, NOT RECRUITING: The study is ongoing (that is, participants are receiving an intervention or being examined), but potential participants are not currently being recruited or enrolled.
COMPLETED: The study has ended normally, and participants are no longer being examined or treated (that is, the "last subject, last visit" has occurred).
TERMINATED: The study has stopped recruiting or enrolling participants early and will not start again. Participants are no longer being examined or treated.
WITHDRAWN: The study stopped early, before enrolling its first participant.

precision medicine

Our pipeline and products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

Read More